Buy­out deal loom­ing, No­vo Nordisk raids As­traZeneca for a new chief to run its strug­gling bio­phar­ma busi­ness

Fresh off the heels of an R&D re­or­ga­ni­za­tion an­nounced last month, Dan­ish drug­mak­er No­vo Nordisk has ap­point­ed As­traZeneca’s Lu­dovic Helf­gott as ex­ec­u­tive vice pres­i­dent of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.